By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Johnson and Johnson Pharmaceutical Research and Development, LLC (NJ) 

920 U.S. Highway 202
P.O. Box 300
Raritan  New Jersey  08869-0602  U.S.A.
Phone: 908-704-4000 Fax: n/a


SEARCH JOBS








Company News
FDA Approves Johnson & Johnson Pharmaceutical Research & Development, LLC (CA)'s (JOBS) INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 8/3/2009 7:45:20 AM
Bayer AG (BAY) and Johnson and Johnson Pharmaceutical Research and Development, LLC (NJ) Release: Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data 11/11/2008 10:09:03 AM
Tekmira Pharmaceuticals Corporation Announces Presentation of Data Using SNALP RNAi Delivery Technology 10/22/2008 8:31:08 AM
Johnson and Johnson Pharmaceutical Research and Development, LLC (NJ) Submits New Drug Application to FDA for Rivaroxaban 7/30/2008 9:45:55 AM
Doribax Shows Shorter Hospital Stays In Ventilator-Associated Pneumonia Patients, Johnson and Johnson Pharmaceutical Research and Development, LLC (NJ) Study 5/16/2008 7:57:28 AM
Sareum Ltd. (SAR.L) Extension of Collaboration with Johnson and Johnson Pharmaceutical R&D (NJ) 3/31/2008 12:16:55 PM
Johnson and Johnson Pharmaceutical R&D (NJ), Basilea Pharmaceutica Key Drug Fails to Get FDA Approval; Stock Dives 3/18/2008 7:04:33 AM
Johnson and Johnson Pharmaceutical Research and Development, LLC (NJ) Says FDA Delays Antibiotic Review by 3 Months 3/7/2008 6:43:49 AM
Johnson and Johnson Pharmaceutical R&D (NJ) New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 1/24/2008 7:31:09 AM
Johnson and Johnson Pharmaceutical R&D (NJ) Release: Three Phase III Trials Show Rivaroxaban Outperformed Enoxaparin in Preventing Venous Thromboembolism After Major Orthopedic Surgery 12/10/2007 10:25:57 AM
12345678
//-->